Zepbound beats Wegovy in head-to-head test

The latest stories trending on MedCity News.

Editor's Pick

Top Story Eli Lilly's Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk's in the increasingly competitive market of obesity medications. Sponsored Not All Oximeters Are Created Equal Presented by Nonin Recent studies show that some popular pulse oximeters perform outside of the FDA guidelines for accuracy.1 Nonin Medical's fingertip technology exceeds FDA guidelines2 and outperforms low-cost and medical-grade oximeters, specifically in patients with dark skin pigmentation, reinforcing how equitable solutions have been a part of Nonin's technology since the beginning.1, 3 Learn More 1. Leeb G, Auchus I, Law T, et al. The performance of 11 fingertip pulse oximeters during hypoxemia in healthy human participants with varied, quantified skin pigment. EBioMedicine. 2024;102:105051.doi:10.1016/j.ebiom.2024.105051 2. Nonin Medical, Inc. Data on File. 3. Bickler P, Feiner J, Severinghaus J. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. Anesthesiology.2005;102(4):715-719. doi:10.1097/00000542-200504000-00004 INVEST 2025: Lock in the Best Rates by Next Friday, December 13! Take advantage of the best rate for the INVEST 2025 in Chicago, May 20-21! Extreme Early Bird ends next Friday, December 13.  Secure your spot! Get Your Ticket at the Best Rate Now

Featured News

Peer Support Platform Fello Secures $10.4M To Combat Loneliness Epidemic Fello's $10.4 million raise includes a seed investment from Glen Tullman's 62Ventures, The Capital Factory Fellowship Fund, Katalyst Capital and Offline Ventures. Video: Battle of the Bulge - Wegovy vs. Zepbound The GLP-1 battle heats up with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk's Wegovy. Why One Investor Still Believes in Retail Health It's been a tumultuous past couple years for retail health companies —but there are still reasons to believe in the convenient model that retail health offers, said Annie Lamont, managing partner and co-founder of Oak HC/FT. A Biotech Startup's Quest to Relieve Pulmonary Mucus Obstruction for Respiratory Care In response to emailed questions, the founders of MucoLife Therapeutics shared their company's approach, which is designed to help people with COPD, cystic fibrosis, asthma, and pulmonary fibrosis. 10 Imperatives of a Medication Intelligence System to Streamline the Pharmacy Lifecycle Focusing on comprehensive strategies and embracing flexible technology solutions arms pharmacy leaders to stay ahead of industry changes, connect teams, and integrate information efficiently.  Healthcare's Next Frontier: Building a Fully Connected Experience It comes down to two simple questions that every health plan should consider: "Are we a company that pays for services and manages risks? Or are we a company that delivers better health for our members?"

Resources

MedCity FemFwd: How Doulas Can Improve Maternal Health Outcomes In this episode, we're joined by Dr. Tiffany Inglis, national medical director for women and children's health at Carelon Health, a subsidiary of Elevance Health. Inglis discusses a paper Elevance Health Public Policy Institute recently published about doulas. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe